Epizyme nets $131.6mm through public stock sale

15:40 EDT 15 Sep 2017 | Elsevier Business Intelligence

Epizyme Inc. (epigenetic cancer therapies) netted $131.6mm through a public offering of 9.18mm common shares at $15.25. The p...

Original Article: Epizyme nets $131.6mm through public stock sale


More From BioPortfolio on "Epizyme nets $131.6mm through public stock sale"

Quick Search

Relevant Topics

The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...